United States Health

AbbVie (NYSE:ABBV) reported third-quarter 2026 net revenue of $17.404 billion, up 10.3% year over year, while GAAP diluted earnings per share increased to $2.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year, while GAAP diluted earnings per share increased 35% to $18.45.

BrightSpring Health Services (NASDAQ:BTSG) reported third-quarter 2026 revenue of $4.213 billion, up 26% year over year, as continuing-operations net income increased to $100.8 million.

Sanofi (NASDAQ:SNY) reported third-quarter 2026 net sales of €14.44 billion, up 16.2% year over year, as business earnings per share increased 22% to €3.55.

AstraZeneca (NASDAQ:AZN) reported third-quarter 2026 revenue of $16.21 billion, up 7% at constant exchange rates, while core earnings per share increased 19% to $2.79.

Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, as growth in key pharmaceutical products supported results.

Eli Lilly and Company (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, beating analyst expectations as strong demand for its weight-loss and diabetes medicines supported growth.

Pediatrix Medical Group (NYSE:MD) reported third-quarter 2026 revenue of $501.4 million, up 1.7% year over year, with net income of $47 million.

HUTCHMED (NASDAQ:HCM) received US Food and Drug Administration Orphan Drug Designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk.

Molecular Partners (NASDAQ:MOLN) plans to reduce its workforce by up to approximately 44%, affecting no more than 55 positions, as it increases its focus on targeted radiotherapy.

Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 revenue growth of 8.4% at actual exchange rates and upgraded its full-year outlook to reflect foreign exchange benefits.

Boston Scientific (NYSE:BSX) reported third-quarter 2026 revenue of $5.138 billion, up 1.5% year over year, while adjusted earnings per share fell short of analysts' expectations at $0.73.